Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: indigo carmine; sorbitol solution (70 per cent) (non-crystallising); disodium edetate; titanium dioxide; glycerol; brilliant scarlet 4r; soya oil; yellow beeswax; gelatin; purified water; partially hydrogenated soya oil; hydrogenated vegetable oil; dl-alpha-tocopherol; butylated hydroxyanisole - isotretinoin ascent is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: butylated hydroxyanisole; sorbitol solution (70 per cent) (non-crystallising); titanium dioxide; gelatin; brilliant scarlet 4r; partially hydrogenated soya oil; glycerol; soya oil; hydrogenated vegetable oil; yellow beeswax; disodium edetate; iron oxide black; dl-alpha-tocopherol; purified water - isotretinoin ascent is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 5 mg - capsule, soft - excipient ingredients: purified water; glycerol; hydrogenated vegetable oil; partially hydrogenated soya oil; butylated hydroxyanisole; gelatin; dl-alpha-tocopherol; titanium dioxide; yellow beeswax; disodium edetate; sorbitol solution (70 per cent) (non-crystallising); soya oil - isotretinoin ascent is indicated for the treatment of patients with severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 40 mg - capsule, soft - excipient ingredients: titanium dioxide; yellow beeswax; purified water; disodium edetate; butylated hydroxyanisole; soya oil; partially hydrogenated soya oil; glycerol; gelatin; dl-alpha-tocopherol; hydrogenated soya oil; sorbitol solution (70 per cent) (non-crystallising); sunset yellow fcf - isotretinoin-ga is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cyctic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: titanium dioxide; butylated hydroxyanisole; gelatin; glycerol; disodium edetate; brilliant scarlet 4r; yellow beeswax; purified water; hydrogenated vegetable oil; indigo carmine; sorbitol solution (70 per cent) (non-crystallising); dl-alpha-tocopherol; soya oil; partially hydrogenated soya oil - isotretinoin-ga is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: gelatin; butylated hydroxyanisole; glycerol; yellow beeswax; titanium dioxide; sorbitol solution (70 per cent) (non-crystallising); iron oxide black; disodium edetate; purified water; brilliant scarlet 4r; partially hydrogenated soya oil; soya oil; hydrogenated vegetable oil; dl-alpha-tocopherol - isotretinoin-ga is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 5 mg - capsule, soft - excipient ingredients: disodium edetate; partially hydrogenated soya oil; glycerol; soya oil; sorbitol solution (70 per cent) (non-crystallising); yellow beeswax; dl-alpha-tocopherol; titanium dioxide; gelatin; hydrogenated vegetable oil; purified water; butylated hydroxyanisole - isotretinoin-ga is indicated for the treatment of patients with severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 40 mg - capsule, soft - excipient ingredients: purified water; dl-alpha-tocopherol; butylated hydroxyanisole; soya oil; glycerol; gelatin; sorbitol solution (70 per cent) (non-crystallising); disodium edetate; titanium dioxide; partially hydrogenated soya oil; hydrogenated soya oil; yellow beeswax; sunset yellow fcf - isotretinoin-as is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cyctic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: dl-alpha-tocopherol; indigo carmine; soya oil; sorbitol solution (70 per cent) (non-crystallising); brilliant scarlet 4r; hydrogenated vegetable oil; gelatin; titanium dioxide; glycerol; yellow beeswax; purified water; butylated hydroxyanisole; disodium edetate; partially hydrogenated soya oil - isotretinoin-as is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: butylated hydroxyanisole; soya oil; dl-alpha-tocopherol; iron oxide black; disodium edetate; sorbitol solution (70 per cent) (non-crystallising); gelatin; titanium dioxide; partially hydrogenated soya oil; yellow beeswax; hydrogenated vegetable oil; purified water; brilliant scarlet 4r; glycerol - isotretinoin-as is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.